Activation of the EGF Receptor by Ligand Binding and Oncogenic Mutations: The “Rotation Model”
Open accessThe DOI matches its Crossref record; 150 of the 150 references it cites were found in a registry or an index.
Abstract
The epidermal growth factor receptor (EGFR) plays vital roles in cellular processes including cell proliferation, survival, motility, and differentiation. The dysregulated activation of the receptor is often implicated in human cancers. EGFR is synthesized as a single-pass transmembrane protein, which consists of an extracellular ligand-binding domain and an intracellular kinase domain separated by a single transmembrane domain. The receptor is activated by a variety of polypeptide ligands such as epidermal growth factor and transforming growth factor α. It has long been thought that EGFR is activated by ligand-induced dimerization of the receptor monomer, which brings intracellular kinase domains into close proximity for trans-autophosphorylation. An increasing number of diverse studies, however, demonstrate that EGFR is present as a pre-formed, yet inactive, dimer prior to ligand binding. Furthermore, recent progress in structural studies has provided insight into conformational changes during the activation of a pre-formed EGFR dimer. Upon ligand binding to the extracellular domain of EGFR, its transmembrane domains rotate or twist parallel to the plane of the cell membrane, resulting in the reorientation of the intracellular kinase domain dimer from a symmetric inactive configuration to an asymmetric active form (the “rotation model”). This model is also able to explain how oncogenic mutations activate the receptor in the absence of the ligand, without assuming that the mutations induce receptor dimerization. In this review, we discuss the mechanisms underlying the ligand-induced activation of the preformed EGFR dimer, as well as how oncogenic mutations constitutively activate the receptor dimer, based on the rotation model.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368 · cited 2×
“Two other mutations are a deletion in which residues from L747 to P753 (L723–P729 in mature EGFR) are replaced with a single serine to give the ∆L747–P753insS mutant [133,135,136], and the mutant ∆S752–I759 (∆S728–I735 in mature EGFR) in which residues 752–759 are deleted [133].”
BackgroundCell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857 · cited 1×
“All these cysteines are present in Subdomain IV [113,124-126].”
BackgroundSignal transduction by receptors with tyrosine kinase activity
Ullrich, A., & Schlessinger, J. (1990) · Cell · doi:10.1016/0092-8674(90)90801-k · Cited by 5,435 · cited 1×
“Ligand binding to the extracellular domain shifts the equilibrium toward the formation of active dimers, and induces kinase stimulation [33-35].”
BackgroundThe Somatic Genomic Landscape of Glioblastoma
Brennan, C. W., Verhaak, R. G. W., McKenna, A., Campos, B., Noushmehr, H., Salama, S. R., Zheng, S., Chakravarty, D., Sanborn, J. Z., Berman, S. H., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.034 · Cited by 5,016 · cited 1×
“Recent genomic studies in GBM and NSCLC patients have identified an additional class of oncogenic mutations caused by deletion of C-terminal coding regions [103,154-156].”
BackgroundCell Signaling by Receptor Tyrosine Kinases
Schlessinger, J. (2000) · Cell · doi:10.1016/s0092-8674(00)00114-8 · Cited by 3,774 · cited 1×
“Furthermore, a modified model has proposed that the receptor monomers are at equilibrium with receptor dimers [33,34].”
BackgroundERBB receptors and cancer: the complexity of targeted inhibitors
Hynes, N. E., & Lane, H. A. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1609 · Cited by 3,313
Epidermal growth factor receptor mutations in lung cancer
Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170 · cited 8×
“Deletion mutants in the intracellular domain have also been found in NSCLC, and various deletions within the range encompassing E746 to I759 (E722 to I735 in mature EGFR) have been identified [133].”
BackgroundInfluential
Cited by
EGFR targeting for cancer therapy: Pharmacology and immunoconjugates with drugs and nanoparticles
Santos, E. D. S., Nogueira, K. A. B., Fernandes, L. C. C., Martins, J. R. P., Reis, A. V. F., Neto, J. D. B. V., Júnior, I. J. D. S., Pessoa, C., Petrilli, R., & Eloy, J. O. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.120082 · Cited by 185
Molecular Regulation and Oncogenic Functions of TSPAN8
Yang, J., Zhang, Z., Lam, J. S. W., Fan, H., & Fu, N. Y. (2024) · Cells · doi:10.3390/cells13020193 · Cited by 11
“The epidermal growth factor receptor (EGFR), which plays a crucial role in many key cellular processes such as cell proliferation, survival, motility, and differentiation [60], has been identified as a strong TSPAN8-binding partner [47].”
BackgroundCholesterol promotes the formation of dimers and oligomers of the receptor tyrosine kinase ROR1
Ward, A., Baeza-Ballesteros, L. J., Schuck, R., García-Murria, M. J., Lamichhane, R., Mingarro, I., & Barrera, F. N. (2026) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.111000 · Cited by 4
Metadata
- Authors
- Purba, E., Saita, E.-I., & Maruyama, I.
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2017-06-02
- Volume
- 6
- Issue
- 2
- Pages
- 13
- ISSN
- 2073-4409 (ISSN-L)
- OpenAlex
- W2620474869
- Cited by
- 205
- References
- 150
- FWCI
- 7.00
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Activation of the EGF Receptor by Ligand Binding and Oncogenic Mutations: The “Rotation Model”. https://app.cochat.ai/papers/10.3390/cells6020013
- The paper
- Purba, E., Saita, E.-I., & Maruyama, I. (2017). Activation of the EGF Receptor by Ligand Binding and Oncogenic Mutations: The “Rotation Model”. Cells. https://doi.org/10.3390/cells6020013
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.